Omics Strategies and Big Data: Transforming Precision Medicine and Systems Biology

Abstract

The convergence of multi-omics strategies and big data analytics is transforming modern healthcare by shifting medicine from a reactive discipline to a proactive, personalized system. This review explores how integrating genomics, transcriptomics, proteomics, and metabolomics provides a holistic view of complex biological systems. While current literature heavily documents theoretical models, a persistent gap remains in translating these high-dimensional architectures into validated healthcare workflows. We highlight the critical role of big data infrastructure, specifically cloud computing and artificial intelligence (AI), in processing massive datasets and we benchmark our approach against existing reviews to emphasize the path toward routine clinical deployment. Through concrete case studies in oncology and metabolic disorders, we illustrate the potential clinical utility of these technologies in advancing precision medicine. Finally, we address persistent challenges including data heterogeneity, privacy concerns, and computational bottlenecks, and discuss future directions required to translate multi-omics insights into routine clinical practice.

1. Introduction

Medicine is undergoing a fundamental paradigm shift from a one-size-fits-all model to an individualized, data-driven discipline known as precision medicine [1]. Historically, clinical decisions relied on generalized symptoms and population averages, which often failed to account for individual biological variability [2,3]. Today, the rise of systems biology has redefined our understanding of health and disease, viewing human physiology as a dynamic network of complex molecular interactions rather than isolated pathways [4,5]. Driving this revolution is an unprecedented explosion of biological data. The rapid drop in high-throughput sequencing costs has democratized access to genomic, transcriptomic, proteomic, and metabolomic profiling. However, capturing this vast molecular landscape generates massive datasets that present significant computational challenges [6]. True precision medicine should generate data while also extracting useful clinical insights from it.

In our review, we examine the current state of multi-omics integration, evaluate the computational infrastructure required to manage big data, and discuss the clinical applications and challenges of translating these technologies into routine patient care. The current biomedical literature highlights a distinct gap between computational development and clinical implementation. Single-layer omics studies dominate research, with genomics (~55%) and transcriptomics (~30%) accounting for most published datasets, and proteomics/metabolomics (~15%) accounting for a smaller volume [7,8]. Integrated multi-omics studies have grown steadily over the last five years. However, a major bottleneck remains; despite numerous papers describing theoretical multi-omics machine learning models, fewer than 5% evaluate real-world clinical cohorts (such as TCGA or iPOP), and very few systems have achieved regulatory approval (such as the FoundationOne Liquid CDx assay) [9,10,11]. This review focuses on this limited translational space to connect data architectures directly to validated clinical outcomes, as compared with other reviews in Table 1.

Stated explicitly, the review question addressed here is: To what extent has the multi-omics big-data literature translated into validated, bedside-deployed clinical tools, and what specific data-infrastructure and governance gaps remain? Unlike prior reviews, which either treat the computational methodology and the clinical application as separate studies (Table 1) or discuss translational gaps qualitatively without quantifying them, this review’s unique focus is to (i) quantify, across the reviewed literature, how much of the field has reached real-world clinical validation (Figure 1); and (ii) connect that quantified gap directly to the specific infrastructure, governance, and explainability requirements needed to close it.

Figure 1. Compositional analysis of the 56 references cited in this review, classified by primary scope. Only the 11% subset annotated in red text on the chart combines multi-omics integration with validation in real patient cohorts, illustrating the translational bottleneck addressed by the current review. [12,13,14,15,16,17].

Figure 1. Compositional analysis of the 56 references cited in this review, classified by primary scope. Only the 11% subset annotated in red text on the chart combines multi-omics integration with validation in real patient cohorts, illustrating the translational bottleneck addressed by the current review. [12,13,14,15,16,17].

Table 1. Comparison of recent literature reviews on multi-omics data integration.

Study	Scope & Core Focus	Analysis of Computational Data Stages	Incorporation of Data Governance Standards	Explanation of Bedside Clinical Interventions
Yetgin et al. [6]	Broad overview of AI and data processing in Omics.	Yes	No	No
Martinez et al. [8]	Computational challenges and hurdles in ML precision medicine.	No	No	No
Abbas et al [12]	Multi-omics computational framework for cancer subtyping.	Yes	No	No
Picard et al. [18]	Strict mathematical classification of ML integration strategies.	Yes	No	No
Yagin et al. [19]	Medical applications of ML data integration.	Yes	No	Yes
Jiang et al. [20]	Network-based Omics in early drug discovery.	No	No	No
Pallikkavaliyaveetil et al. [21]	Data-limited ML for drug discovery	Yes	No	No
Alemu et al. [22]	Gene-environment interactions in non-communicable diseases.	No	No	Yes
Lac et al. [23]	Deep learning and statistical models for multimodal omics.	Yes	No	No
Baysoy et al. [24]	Technical landscape and applications of single-cell multi-omics.	No	No	No
Current review	End-to-end translation from data stages to clinical application.	Yes	Yes	Yes

Table 1. Comparison of recent literature reviews on multi-omics data integration.

Study	Scope & Core Focus	Analysis of Computational Data Stages	Incorporation of Data Governance Standards	Explanation of Bedside Clinical Interventions
Yetgin et al. [6]	Broad overview of AI and data processing in Omics.	Yes	No	No
Martinez et al. [8]	Computational challenges and hurdles in ML precision medicine.	No	No	No
Abbas et al [12]	Multi-omics computational framework for cancer subtyping.	Yes	No	No
Picard et al. [18]	Strict mathematical classification of ML integration strategies.	Yes	No	No
Yagin et al. [19]	Medical applications of ML data integration.	Yes	No	Yes
Jiang et al. [20]	Network-based Omics in early drug discovery.	No	No	No
Pallikkavaliyaveetil et al. [21]	Data-limited ML for drug discovery	Yes	No	No
Alemu et al. [22]	Gene-environment interactions in non-communicable diseases.	No	No	Yes
Lac et al. [23]	Deep learning and statistical models for multimodal omics.	Yes	No	No
Baysoy et al. [24]	Technical landscape and applications of single-cell multi-omics.	No	No	No
Current review	End-to-end translation from data stages to clinical application.	Yes	Yes	Yes

Table 1 positions this review qualitatively against nine recent surveys. To make the added value of the present review explicit, Table 2 provides a detailed, study-by-study statement of the reported scope, remaining gap, and specific contribution of the current work relative to the six most closely related reviews.

Table 2. Added value of the current review relative to the most closely related prior reviews identified in Table 1.

Study	Primary Contribution	Reported Analytical Scope	Gap Relative to Current Review	Added Value of Current Review
Checa-Ros et al. (2025) [5]	In silico medicine and -omics strategies in nephrology	Narrative, single-disease (CKD), non-quantitative	Concept-level; no cross-study literature quantification or infrastructure/governance comparison	Extends the same clinical domain into a quantified, end-to-end computational-to-bedside pipeline
Yetgin (2025) [6]	AI and data processing across omics layers	Broad, technology-first narrative	No governance or bedside-translation analysis (Table 1)	Adds the governance and bedside-translation layers absent from
Martinez-Garcia & Hernandez-Lemus (2022) [8]	Data-integration challenges for machine learning in precision medicine	Computational-hurdles focus; no disease case studies	No disease-specific case studies or quantitative synthesis of the literature	Anchors the same computational hurdles to concrete oncology and CKD/T2DM case studies with a quantified evidence-gap analysis
Li-Pook-Than & Snyder (2013) [10]	iPOP integrated personal omics profiling cohort	Single landmark cohort, perspective article, predates current cloud/AI tooling	Predates cloud-native infrastructure (GA4GH, containerized pipelines) and explainable-AI standards	Updates the iPOP-era vision with current cloud, governance and explainable-AI frameworks
Li et al. (2026) [13]	Multi-omics and AI in diabetic kidney disease	Narrative, single-disease (DKD)	Confined to DKD; no cross-disease comparison, infrastructure/governance analysis, or quantitative literature synthesis	Generalizes the DKD example within a broader, quantified, cross-disease (oncology plus CKD/T2DM) framework
Picard et al. (2021) [18]	Mathematical taxonomy of multi-omics integration strategies	Rigorous but purely methodological	Does not connect integration mathematics to regulatory status or bedside deployment	Applies the same taxonomy to regulatory-approved assays and an active clinical trial
Jiang et al. (2025) [20]	Network-based multi-omics integration in drug discovery	Domain-restricted to drug discovery	Does not cover diagnostic/prognostic clinical workflows, infrastructure, or governance	Broadens scope to diagnostic and prognostic bedside applications beyond drug discovery
Current review	End-to-end translation from multi-omics data stages to clinical application	Qualitative comparison (Table 1) plus quantitative bibliometric synthesis (Figure 1) spanning governance and explainable-AI layers	—	—

To move beyond a purely qualitative positioning statement, we quantified the composition of the 56 references cited in this review by primary scope. Approximately 30% (17/56) describe methodological or conceptual frameworks for multi-omics integration without a disease-specific application; 25% (14/56) report a disease-specific translational study; 20% (11/56) address big-data infrastructure, governance, or privacy; 11% (6/56) focus on explainable AI methodology; 9% (5/56) are single-omics-layer technical reports; and the remaining 5% (3/56) provide general precision-medicine context (Figure 1).

Critically, only 6 of these 56 references (11%) report a multi-omics analysis that was both integrated across two or more molecular layers and was validated against real patient cohorts or regulatory-grade evidence [12,13,14,15,16,17]; the remainder either model a single omics layer, discuss infrastructure in the abstract, or address multi-omics integration purely at the methodological level. This quantified translational gap, rather than the integration mathematics itself, is the specific bottleneck that the present review targets, and it is not explicitly measured in any of the six most closely related reviews summarized in Table 2.

2. Multi-Omics Data Integration

While individual “omics” fields offer valuable insights, single-layer analyses inherently fail to capture the holistic complexity of human biology [25]. Genomics reveals inherited predispositions, but it cannot capture the dynamic environmental responses reflected in the transcriptome, proteome, or metabolome [16]. Multi-omics data integration bridges these layers, tracing the flow of biological information from genetic code to functional phenotype. By combining these distinct data types, researchers can move past simple correlations to map out complex associative and potential regulatory biological networks, shifting how we understand disease mechanisms.

Computationally, integrating these massive, disparate datasets requires robust mathematical frameworks capable of handling high-dimensional data. Methods generally fall into five core strategies: early, late, intermediate, model-based and multi-staged integration [18]. For the scope of this review, we focus primarily on the three main data-stage frameworks: early, late and intermediate methods. Early integration combines all data types into a single matrix before analysis, which is simple but often loses layer-specific nuances. The model can become overwhelmed by the largest data type (usually genomics or transcriptomics), while missing signals from smaller layers (like metabolomics) [18]. Late integration isolates the analysis of individual omics layers, relying on ensemble methods (e.g., averaging or voting) to combine final predictions, though it risks missing cross-layer interactions [18,19]. Intermediate integration resolves these limitations mathematically; instead of flattening raw matrices, it deploys joint matrix factorization and deep autoencoders to project distinct layers into a shared, lower-dimensional feature space [18,20]. These methods preserve the unique statistical properties of each biological tier while uncovering shared underlying features. The remaining two strategies; model-based integration (which incorporates prior biological pathways directly into machine learning models) and multi-staged integration (which performs step-wise hierarchical filtering across layers) are excluded from deep analysis here, as they represent specialized hybrid frameworks rather than pure data-stage merging strategies [18,20].

Large-scale public repositories have been instrumental in benchmarking and validating these integration frameworks. The Cancer Genome Atlas (TCGA) stands as a prime example, offering matched genomic, transcriptomic, and epigenetic profiles across thousands of tumor samples [11]. By applying multi-omics integration to TCGA data, computational biologists have successfully identified novel molecular subtypes of cancer that appear identical under a microscope but behave differently clinically [14]. This integration of diverse biological layers ultimately fuels the discovery of robust, multi-dimensional biomarkers and targeted clinical therapies.

3. Big Data Infrastructure

Managing the sheer volume and velocity of multi-omics data requires a comprehensive overhaul of traditional computational infrastructure. A single human genome generates dozens of gigabytes of raw data [26]; when scaled across clinical cohorts and layered with transcriptomic and proteomic profiles, data storage and processing needs quickly exceed the capacity of local servers [8]. Cloud computing platforms, such as Amazon Web Services (AWS), Google Cloud Platform (GCP), and Microsoft Azure, have become indispensable in solving these bottlenecks. Crucially, the hosting landscape has begun to evolve from general purpose hosting towards purpose-built life science verticals, utilizing platforms like AWS HealthOmics for automated bioinformatics pipeline orchestration and Google Cloud’s Healthcare API to ingest multimodal datasets at scale [27,28]. These platforms offer scalable storage, massive parallel processing capabilities, and secure environments that allow global research consortia to collaborate and analyze massive datasets without the financial burden of maintaining physical supercomputers [29].

Once this data is securely hosted in the cloud, artificial intelligence (AI) serves as the primary engine for pattern extraction. However, as clinical translation relies on practical data governance frameworks, modern architectures require Global Alliance for Genomics and Health (GA4GH) standards, containerized workflow languages such as Nextflow, Workflow Description Language (WDL) and git-based version control, in order to guarantee reproducible and interoperable pipelines across separate institutions [30,31]. Furthermore, standard metadata schemas preserve biological provenance, while federated learning systems enable secure, decentralized clinical data sharing without exposing raw sequence files [32,33]. Under this standardized framework, researchers bypass the traditional mathematical “curse of dimensionality,” where the number of biological variables vastly outnumbers the number of patients [34]. To navigate this, researchers deploy classical ML architectures like Random Forests and Support Vector Machines for robust feature selection and sample classification [5,21]. For deeper, non-linear biological networks, distinct deep learning frameworks are strictly tailored to the underlying biological data types rather than applied universally. For instance, Convolutional Neural Networks (CNNs) like DeepVariant process sequencing alignments reframed as image-like pileup matrices to accurately detect single nucleotide variants [35]. In structural biochemistry, Transformer-based models like AlphaFold3 process tokenized amino acid matrices and molecular graphs to predict 3D protein–ligand binding configurations [29]. Finally, for clinical prognosis, specialized Deep Neural Networks (DNNs) like DeepSurv integrate high-dimensional clinical omics streams with non-linear Cox proportional hazards models to forecast patient survival trajectories [36]. Figure 2 outlines the steps for using multi-omics data in clinical practice. The diagram shows raw molecular layers (A), the computational methods used for integration (B), and the resulting patient risk report (C).

Figure 2. A Multi-Omics Integrative Framework for Clinical Risk Stratification: The figure outlines the sequential workflows that translate multi-omics information into clinically applicable data.

4. Clinical Translation and Disease Case Studies

The clinical utility of multi-omics big data is moving past broad theoretical models to drive major advancements in clinical oncology, shifting patient care from a reactive to a proactive and precise management. A primary case study lies in the molecular stratification of Breast Invasive Carcinoma using public data repositories like The Cancer Genome Atlas (TCGA) [15]. In these workflows, computational frameworks combine matched genomic copy number variations (CNVs), transcriptomic RNA-Seq profiles, and proteomic mass spectrometry arrays derived from identical tumor tissue samples [12,15]. By applying computational methods such as Joint Matrix Factorization (JMF) and deep autoencoders, algorithms can simultaneously cluster these distinct data layers without losing cross layer statistical relationships [23]. This multi-omics approach would improve patient stratification. While traditional microscopy classifies breast tumors based on surface receptors (PR, ER and HER2), multi-omics clustering reveals distinct molecular subtypes (such as Basal-like and Luminal A & B) within identical receptor-positive cohorts [16,37]. This allows oncologists to better predict therapeutic resistance, as Basal-like tumors (which present clinically as Triple-Negative Breast Cancer [TNBC]) commonly fail to respond to standard hormone therapies but show high sensitivity to platinum-based chemotherapy combinations, thereby improving patient survival and long-term remission outcomes [16,38]. This clinical translation is supported by real-world, high-dimensional frameworks like the FDA-approved FoundationOne Liquid CDx assay and the landmark I-PREDICT precision oncology trial [9,39].

Beyond oncology, this integrated systems approach is fundamentally reshaping the prevention and management of complex metabolic diseases such as Type 2 Diabetes Mellitus (T2DM) and Diabetic Kidney Disease (DKD). Traditional clinical tools, such as HbA1c tracking or estimated Glomerular Filtration Rate (eGFR) calculation, sometimes fail to capture early, sub-clinical metabolic and microvascular dysregulation [40]. To resolve this limitation, researchers leverage large-scale datasets such as the ‘Integrative Personal Omics Profile (iPOP)’ cohort, among others, to merge genomic polygenic risk scores with longitudinal plasma proteomics, untargeted lipidomic arrays, and urinary proteomics [10,17,41]. Computational pipelines process these high-dimensional streams using supervised machine learning classifiers, including Random Forests and Support Vector Machines, to map early pathological fingerprints [21]. The clinical utility of this multi-omics methodology lies in the ability to detect diabetic nephropathy long before symptoms such as microalbuminuria or drops in eGFR appear [13]. By flagging early changes in specific plasma and urine markers, clinicians can identify which patients face the highest risk for rapid renal decline [13]. This would enable the timely and precise administration of nephroprotective and anti-diabetic agents like sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), successfully altering the patient’s long-term disease course before irreversible damage occurs [42,43]. This multi-layered architecture is actively validated at scale by the ongoing NIH Nutrition for Precision Medicine landmark multi-omics cohort trial [44].

5. Challenges and Future Directions

Despite the immense promise of multi-omics big data, several critical limitations must be resolved before its full potential can be realized in routine clinical care. From a computational perspective, data heterogeneity and standardization remain massive hurdles [8]. Different laboratories use varying experimental protocols, sequencing depths, and extraction techniques, introducing significant “batch effects” that can skew mathematical models and lead to false-positive discoveries [45]. To resolve this, standard multi-omics pipelines must mandate uniform preprocessing and computational normalization protocols, leveraging empirical Bayes frameworks like ComBat or Surrogate Variable Analysis (SVA) to systematically eliminate non-biological batch variance [46,47]. Furthermore, integrating datasets across completely different biological modalities involves resolving massive discrepancies in data scale and noise levels [21,48]. Translating raw data files into standardized, clinically actionable reports requires universally accepted data formats, reproducible pipelines, and rigorous benchmarking standards that do not yet exist at scale.

Parallel to these technological hurdles, ethical, legal, and institutional challenges persist. High-throughput sequencing exposes deeply personal, immutable genetic information, raising substantial concerns regarding patient data privacy, informed consent, and security against unauthorized access or genetic discrimination [49]. Facilitating the open data-sharing necessary to train robust AI models, while strictly protecting patient anonymity across international borders, requires sophisticated cryptographic frameworks. Clinically, the field faces an interpretation bottleneck. Most practicing physicians struggle to trust complex, uninterpretable “black box” multi-omics network models, as making blind high-stakes clinical interventions based on hidden node computations poses massive ethical and safety risks [50]. To make these models transparent for bedside decision-making, current developer architectures deploy Explainable AI (XAI) local feature attribution tools (such as SHAP [Shapley Additive exPlanations] or LIME [Local interpretable Model-agnostic Explanations] [51,52,53]). These tools convert black boxes into intuitive feature weight maps that reveal exactly which molecular layer or biomarker drove a patient’s risk calculation [51,54]. Ultimately, these XAI summaries must be translated into standardized clinical reports and embedded as automated Clinical Decision Support (CDS) alerts within Electronic Health Records (EHRs), providing a practical, transparent roadmap for clinicians in real-world practice [51,52,55].

Looking ahead, the future of precision medicine lies in capturing biological systems with higher resolution and spatial context. Emerging single-cell multi-omics technologies are revolutionizing the field by allowing researchers to analyze genomic, transcriptomic, and proteomic layers simultaneously within individual cells, exposing the hidden diversity within complex tissue microenvironments [24]. Furthermore, spatial transcriptomics adds a crucial structural dimension, mapping exactly where these molecular activities occur within the physical architecture of a tissue [56]. By pairing these high-resolution single-cell techniques with advanced cloud computing and explainable AI models, the next generation of systems biology will move past broad tissue averages to deliver accurate, localized, and dynamically responsive patient care.

6. Conclusions

The convergence of multi-omics data integration, cloud-scalable infrastructure, and advanced artificial intelligence represents a monumental shift toward the realization of true precision medicine. By moving beyond single-variable methodologies, these computational frameworks and deep learning models support the ongoing translation of massive biological datasets into tangible clinical applications, such as multidimensional biomarker discovery and proactive metabolic risk stratification. However, a cautious approach remains necessary as these technologies transition from the research laboratory to the patient’s bedside. The path forward is still limited by systemic challenges in data standardization, batch effects, clinical interpretation, and patient data privacy. For multi-omics to successfully guide routine diagnostic and therapeutic decisions, the medical and computational communities must collaboratively develop standardized, reproducible pipelines, secure ethical sharing frameworks, and explainable AI tools that clinicians can easily interpret and act upon.